Drug makers are developing pill version of weight-loss drugs, WSJ reports

The development of tablet versions for injectable weight-loss medicines is one of the most in-demand areas of drug research, Peter Loftus of The Wall Street Journal reports. Eli Lilly (LLY), Novo Nordisk (NVO), and Pfizer (PFE) are among a few of the company’s developing the drug. Novo Nordisk’s semaglutide is farthest along to developing a tablet form, with the company planning to ask U.S. and European drug regulators to approve the tablet later this year.